- INHIBITORS OF HEPATITIS C VIRUS REPLICATION
-
The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
- -
-
-
- Pyridines IRAK4 inhibitors, preparation method and application thereof (by machine translation)
-
The invention belongs to the field of medicine, in particular to a formula (I) of the structural features of pyridine of compound or its pharmaceutically acceptable salt, preparation method thereof, and their use as IRAK4 inhibitors. Experimental results show that, the compound of the invention IRAK4 has prominent inhibit function, can be used for the treatment of autoimmune disease, inflammatory disease, cancer, autoimmune disease and thromboembolism as heterogeneous. (by machine translation)
- -
-
-
- Chemoselective hydrogenation of functionalized nitroarenes using MOF-derived co-based catalysts
-
The synthesis, characterization, and application of nitrogen-doped carbon supported Co catalysts in selective hydrogenation of nitroarenes are described. The cobalt-based catalysts are prepared by simple pyrolysis of ZIF-67, a typical MOF material, under inert atmosphere. Physicochemical properties of the Co/C-N catalysts have been investigated by X-ray diffraction, elemental analysis, atomic absorption spectroscopy, scanning electron microscopy, transmission electron microscopy, Fourier transform infrared spectroscopy, and X-ray photoelectron spectroscopy. The Co-based materials were found to be highly efficient in the chemoselective hydrogenation of nitroarenes. A broad range of substituted nitroarenes are converted to the corresponding anilines in excellent yields under industrially viable conditions with other reducing groups remaining intact. In situ ATR-IR and XPS characterizations reveal that the Co-N centers present in the catalyst favor the preferential adsorption of nitro groups, leading to this unique chemoselectivity. The kinetic parameters of 4-nitrostyrene hydrogenation over the Co/C-N catalyst were investigated.
- Wang, Xi,Li, Yingwei
-
-
- INHIBITORS OF HEPATITIS C VIRUS REPLICATION
-
The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
- -
-
Page/Page column 65
(2010/11/04)
-
- QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION
-
Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.
- -
-
Page/Page column 139
(2008/06/13)
-
- SUBSTITUTED-3-CYANO-[1.7],[1.5], AND [1.8]-NAPHTHYRIDINE INHIBITORS OF TYROSINE KINASES
-
This invention provides compounds of formula (I) having structure (a) wherein A'' is a diavalent moiety selected from the group (a, b, c) which are useful as inhibitors of protein tyrosine kinase.
- -
-
-
- HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS
-
Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.
- -
-
-
- Aminopyridine compounds
-
An aminopyridine compound represented by the formula: STR1 wherein n represents 0 or 1; Z represents =S, =NCN or =CHNO2 ; R1 represents --NR3 R4, --NHNR3 R4, --NHCONHR3 or --NHSO2 R3 ; R2 represents H, or substituted or unsubstituted alkyl; R3 and R4, which may be the same or different, represent H, substituted or unsubstituted alkyl, aryl, substituted or unsubstituted acyl or alkoxycarbonyl group; and R3 and R4 may form a heterocyclic ring together with a nitrogen atom to which R3 and R4 are bound, through another heteroatom or without it; an optical isomer thereof or art acid salt thereof, which is excellent in pharmacological effect and repressed in side effects as a drug for circulatory diseases.
- -
-
-
- Aminopyridine compounds
-
An aminopyridine compound represented by the formula: STR1 wherein n represents 0 or 1; Z represents =S, =O, =NCN or =CHNO2 ; R1 represents --CN, --NR3 R4, --CONR3 R4, --NHNR3 R4, --NHCONHR3, --NHSO2 R3 or --SR3 ; R2 represents H, or substituted or unsubstituted alkyl; R3 and R4, which may be the same or different, represent H, substituted or unsubstituted alkyl, aryl, substituted or unsubstituted acyl or alkoxycarbonyl group; and R3 and R4 may form a heterocyclic ring together with a nitrogen atom to which R3 and R4 are bound, through another heteroatom or without it; or an acid salt thereof, which is excellent in pharmacological effect and repressed in side effects as a drug for circulatory diseases.
- -
-
-